Market Cap (In CNY)
7.45 Billion
Revenue (In CNY)
1.56 Billion
Net Income (In CNY)
509.21 Million
Avg. Volume
2.29 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 44.01-79.08
- PE
- -
- EPS
- -
- Beta Value
- 2.458
- ISIN
- CNE100003Y57
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Wennian Wu
- Employee Count
- -
- Website
- https://www.kangh.com
- Ipo Date
- 2020-06-16
- Details
- Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
More Stocks
-
ACE
-
MITT-PA
-
CHEMPLASTSChemplast Sanmar Limited
CHEMPLASTS
-
9590Armah Sports Co.
9590
-
EASTW
-
ACLN
-
ACESOFTAce Software Exports Limited
ACESOFT
-
002037